Detection of anti-nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors

Anti-nucleocapsid (N) antibody assays can be used to estimate SARS-CoV-2 infection prevalence in regions employing anti-spike based COVID-19 vaccines. However, poor sensitivity of anti-N assays in detecting infections after vaccination (VI) has been reported. To support serological monitoring of infections, including VI, in a large blood donor cohort (N=142,599), we derived a lower cutoff for identifying previous infection using the Ortho VITROS Anti-SARS-CoV-2 Total-N Antibody assay, improving sensitivity while maintaining specificity >98%. Sensitivity was validated in samples donated after self-reported infections diagnosed by a swab-based test. Sensitivity for first infections in unvaccinated donors was 98.1% (95% CI: 98.0,98.2) and for VI was 95.6% (95.6,95.7), using the standard cutoff. Regression analysis showed sensitivity was reduced in the Delta compared to Omicron period, in older donors, asymptomatic infections, [≤]30 days after infection and for VI. The standard Ortho anti-N threshold demonstrated good sensitivity, which was modestly improved with the revised cutoff.

[1]  C. V. von Bartheld,et al.  An Explanation for Reports of Increased Prevalence of Olfactory Dysfunction with Omicron: Asymptomatic Infections. , 2023, The Journal of infectious diseases.

[2]  B. Biggerstaff,et al.  Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications , 2023, Microbiology spectrum.

[3]  Marion C Lanteri,et al.  Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022 , 2023, MMWR. Morbidity and mortality weekly report.

[4]  O. Laeyendecker,et al.  SARS‐CoV‐2 seroprevalence among blood donors in Uganda: 2019–2022 , 2023, Transfusion.

[5]  Jens K. Boldsen,et al.  Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study , 2022, The Lancet Regional Health - Europe.

[6]  N. Ohmagari,et al.  Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants , 2022, Journal of Infection.

[7]  D. Follmann,et al.  Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.

[8]  Jue Liu,et al.  Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis , 2022, Vaccines.

[9]  J. Opsomer,et al.  Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021. , 2022, JAMA.

[10]  P. Saá,et al.  How do we …form and coordinate a national serosurvey of SARS‐CoV‐2 within the blood collection industry? , 2022, Transfusion.

[11]  B. Biggerstaff,et al.  Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications , 2022, Emerging infectious diseases.

[12]  Samuel S. Shepard,et al.  Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[13]  Marcio K. Oikawa,et al.  Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil , 2022, BMC Infectious Diseases.

[14]  H. Ullum,et al.  Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection , 2022, International Journal of Infectious Diseases.

[15]  A. Laxmaiah,et al.  Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study , 2021, PLoS medicine.

[16]  H. Whitaker,et al.  Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off , 2021, medRxiv.

[17]  E. Sabino,et al.  Intense SARS-CoV-2 transmission among affluent Manaus residents preceded the second wave of the epidemic in Brazil , 2021, The Lancet Global Health.

[18]  Noam Brown,et al.  Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. , 2021, JAMA.

[19]  S. Kleinman,et al.  Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Weizhong Yang,et al.  Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study , 2021, The Lancet.

[21]  Marcio K. Oikawa,et al.  Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic , 2020, Science.

[22]  B. Custer,et al.  Research initiatives of blood services worldwide in response to the covid‐19 pandemic , 2020, Vox sanguinis.

[23]  S. Ladhani,et al.  Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection , 2020, bioRxiv.

[24]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[25]  B. Gladen,et al.  Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.